Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: the 2010 GLADAOF Lecture

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: the 2010 GLADAOF Lecture

Author Fernando Arevalo, J. Google Scholar
Sanchez, Juan G. Google Scholar
Lasave, Andres F. Google Scholar
Wu, Lihteh Google Scholar
Maia, Mauricio Autor UNIFESP Google Scholar
Bonafonte, Sergio Google Scholar
Brito, Miguel Google Scholar
Alezzandrini, Arturo A. Google Scholar
Restrepo, Natalia Google Scholar
Berrocal, Maria H. Google Scholar
Saravia, Mario Google Scholar
Farah, Michel Eid Autor UNIFESP Google Scholar
Fromow-Guerra, Jans Google Scholar
Morales-Canton, Virgilio Google Scholar
Institution Caracas Clin Opthalmol Ctr
INIO
Inst Cirugia Ocular
Universidade Federal de São Paulo (UNIFESP)
Ctr Oftalmol Bonafonte
IDEO
Univ Buenos Aires
Univ Puerto Rico
Hosp Univ Austral
Asociac Evitar Ceguera Mexico 04030
Abstract This paper demonstrates multiple benefits of intravitreal bevacizumab (IVB) on diabetic retinopathy (DR) including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) at 24 months of followup. This is a retrospective multicenter interventional comparative case series of intravitreal injections of 1.25 or 2.5 mg of bevacizumab for DME, PDR without tractional retinal detachment (TRD), and patients who experienced the development or progression of TRD after an intravitreal injection of 1.25 or 2.5 mg of bevacizumab before vitrectomy for the management of PDR. the results indicate that IVB injections may have a beneficial effect on macular thickness and visual acuity (VA) in diffuse DME. Therefore, in the future this new therapy could complement focal/grid laser photocoagulation in DME. in PDR, this new option could be an adjuvant agent to panretina photocoagulation so that more selective therapy may be applied. Finally, TRD in PDR may occur or progress after IVB used as an adjuvant to vitrectomy. Surgery should be performed 4 days after IVB. Most patients had poorly controlled diabetes mellitus associated with elevated HbA1c, insulin administration, PDR refractory to panretinal photocoagulation, and longer time between IVB and vitrectomy.
Language English
Sponsor Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas, Venezuela
Date 2011-01-01
Published in Journal of Ophthalmology. New York: Hindawi Publishing Corporation, 13 p., 2011.
ISSN 2090-004X (Sherpa/Romeo, impact factor)
Publisher Hindawi Publishing Corporation
Extent 13
Origin http://dx.doi.org/10.1155/2011/584238
Access rights Open access Open Access
Type Review
Web of Science ID WOS:000306790100022
URI http://repositorio.unifesp.br/handle/11600/33206

Show full item record




File

Name: WOS000306790100022.pdf
Size: 4.831Mb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account